Trial Profile
A study of recombinant human hyaluronidase for the treatment of primary immunodeficiency disorders in real world patient population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2016 New trial record
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology